Clinical Trial Search

Primary: Investigator Global Assessment of Aesthetic Improvement — 0.7; 0.9; 1.1; 0.5 units on a scale

Primary: Number of Participants That Were 2-level Composite (CR-PCSS and PR-PCSS) Responders During the Observation Phase — 19; 0; 16; 0 Participants

Primary: Percentage of Composite Responders of at Least 2-Level Improvement of Severity — 20; 3 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 58; 29; 43; 45 Participants

Primary: Plasma AUX-I and AUX-II Concentrations — NA mmol/L

Primary: The Proportion of Participants With Improved (+1 or Better) Score on I-GAIS for Either Posterolateral Thigh — 58 Participants

Primary: Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 22 — 1.08; 1.10; 0.75; 0.50 score on a scale

Primary: 2-level Composite Responders for the Target Buttock — 16; 4; 194; 209 Participants — p=0.006

Primary: Investigator Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) 2-level Responders — 6; 131; 8; 125 Participants

Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm

Primary: Proportion of Subjects With ≥1-point Improvement on Investigator Global Aesthetic Improvement Scale (I-GAIS) at Day 90 (Buttocks) — 3; 2 Participants

Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473

Primary: Modified Patient and Observer Scar Assessment Scale Color Component Comparing Change From Baseline to Week 12. — -2.33 score on a scale

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Mortality — 11 Participants

Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change

Primary: Percentage of 1-Level Responders (+1 or Better Score) on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) for Either Buttock or Either Thigh — 85.7; 87.5…

Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)

Primary: 2-level Composite Responders for the Target Buttock — 12; 1; 202; 205 Participants — p=0.002

Primary: The Number of Participants With Grade 1 or Higher ("Improved, Much Improved, Very Much Improved") in Investigator-assessed Global Aesthetic Improvement Scale (GAIS) at…

Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares

Primary: The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort — 0; 0; 0 Participants

Primary: Improvement in Global Aesthetic Appearance of Cellulite in Treated Areas, as Assessed by Study Investigator Evaluations — 11; 7; 4; 16 Investigator Assessments

Primary: Duration of Direct Sunlight Exposure Between 10:00 and 18:00 Hours on Days When no Pain Was Experienced (Pain Score of 0). — 69.4; 40.8 hours

Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001

Primary: The Mean Change From Baseline to 3 Months in Cellulite Severity Scale (CSS) Score for Participants — 1.5 score on a scale — p=.0001

Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent

Primary: Change in Aesthetic Appearance From Baseline — 0.97 score on a scale

Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients

Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale